LT4106757T - Neutrofilų elastazės inhibitoriaus alvelestato panaudojimas kvėpavimo sistemos ligų, nulemtų alfa-1 antitripsino nepakankamumo, gydymui - Google Patents

Neutrofilų elastazės inhibitoriaus alvelestato panaudojimas kvėpavimo sistemos ligų, nulemtų alfa-1 antitripsino nepakankamumo, gydymui

Info

Publication number
LT4106757T
LT4106757T LTEPPCT/GB2021/050653T LTGB2021050653T LT4106757T LT 4106757 T LT4106757 T LT 4106757T LT GB2021050653 T LTGB2021050653 T LT GB2021050653T LT 4106757 T LT4106757 T LT 4106757T
Authority
LT
Lithuania
Prior art keywords
elastasis
alvelestat
neutrophil
inhibitor
alpha
Prior art date
Application number
LTEPPCT/GB2021/050653T
Other languages
English (en)
Lithuanian (lt)
Inventor
Jacqueline PARKIN
Original Assignee
Mereo Biopharma 4 Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=78083570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4106757(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB2005519.0A external-priority patent/GB202005519D0/en
Priority claimed from GBGB2005520.8A external-priority patent/GB202005520D0/en
Application filed by Mereo Biopharma 4 Limited filed Critical Mereo Biopharma 4 Limited
Publication of LT4106757T publication Critical patent/LT4106757T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
LTEPPCT/GB2021/050653T 2020-04-16 2021-03-16 Neutrofilų elastazės inhibitoriaus alvelestato panaudojimas kvėpavimo sistemos ligų, nulemtų alfa-1 antitripsino nepakankamumo, gydymui LT4106757T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2005519.0A GB202005519D0 (en) 2020-04-16 2020-04-16 Elastase inhibition
GBGB2005520.8A GB202005520D0 (en) 2020-04-16 2020-04-16 Elastase inhibition
US202062706195P 2020-08-04 2020-08-04
PCT/GB2021/050653 WO2021209739A1 (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency

Publications (1)

Publication Number Publication Date
LT4106757T true LT4106757T (lt) 2023-11-10

Family

ID=78083570

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/GB2021/050653T LT4106757T (lt) 2020-04-16 2021-03-16 Neutrofilų elastazės inhibitoriaus alvelestato panaudojimas kvėpavimo sistemos ligų, nulemtų alfa-1 antitripsino nepakankamumo, gydymui

Country Status (16)

Country Link
US (2) US20230218596A1 (https=)
EP (2) EP4252850A3 (https=)
JP (1) JP2023522010A (https=)
AU (1) AU2021256835A1 (https=)
DK (1) DK4106757T3 (https=)
ES (1) ES2962498T3 (https=)
FI (1) FI4106757T3 (https=)
HR (1) HRP20231065T1 (https=)
HU (1) HUE064089T2 (https=)
IL (1) IL297211B2 (https=)
LT (1) LT4106757T (https=)
MX (1) MX2022012942A (https=)
PL (1) PL4106757T3 (https=)
PT (1) PT4106757T (https=)
SI (1) SI4106757T1 (https=)
WO (2) WO2021209739A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2613460B (en) * 2020-04-20 2025-07-23 Lloyd Hung Loi Tran Pharmaceutical Compositions for use in methods for the prophylaxis or treatment of COVID such as COVID-19; and compound for use in the treatment of a
EP4452303A4 (en) * 2021-12-20 2025-11-12 Tiakis Biotech Ag USE OF ELAFINE IN THE TREATMENT OF COVID-19
CN116407640B (zh) * 2023-03-03 2025-10-31 河南真实生物科技有限公司 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物
WO2025056602A1 (en) * 2023-09-11 2025-03-20 Elastin Biosciences Ltd. Pharmaceutical compositions and use thereof in treatment of conditions and diseases related to elastin deficiency and/or aging
WO2025078838A1 (en) 2023-10-11 2025-04-17 Mereo Biopharma 4 Limited Alvelestat and alpha- 1 antitrypsin for treating respiratory disorders
AU2024406526A1 (en) 2023-12-21 2026-04-16 Mereo Biopharma 4 Limited Use of alvelestat in specific patients
GB202319953D0 (en) 2023-12-22 2024-02-07 Mereo Biopharma 4 Ltd Tablet formulations involving alvelestat
KR20250172196A (ko) * 2024-05-31 2025-12-09 고려대학교 산학협력단 폐 계면활성제 및 항섬유화제를 포함하는 폐섬유증의 예방 또는 치료용 조성물 및 이의 제조방법
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674708A (en) 1989-06-23 1997-10-07 Trustees Of The University Of Pennsylvania α-1-antichymotrypsin analogues having elastase inhibitory activity
AU1581692A (en) 1991-03-01 1992-10-06 Protein Engineering Corporation Inhibitors of human neutrophil elastase and human cathepsin g
DE69229552T2 (de) 1991-05-23 1999-12-23 Merrell Pharmaceuticals Inc., Cincinnati Hemmstoffe für kathepsin-g und elastase zur verhütung von bindegewebsabbau
US5216022A (en) 1991-12-19 1993-06-01 Cortech, Inc. Aromatic esters of phenylenedialkanoates as inhibitors of human neutrophil elastase
EP0636144A1 (en) 1992-04-16 1995-02-01 Zeneca Limited Alpha-aminoboronic acid peptides and their use as elastase inhibitors
US5486529A (en) 1992-04-16 1996-01-23 Zeneca Limited Certain pyridyl ketones for treating diseases involving leukocyte elastase
GB9307555D0 (en) 1992-04-16 1993-06-02 Zeneca Ltd Heterocyclic compounds
US5441960A (en) 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
DE69314169T2 (de) 1992-04-16 1998-01-15 Zeneca Ltd Peptide mit eine alphaaminoboronaire gruppe and ihre verwendung als elastasehemmer
GB9211783D0 (en) 1992-06-04 1992-07-15 Ici Plc Amide derivatives
GB9214053D0 (en) 1992-07-02 1992-08-12 Ici Plc Heterocyclic amides
GB9402680D0 (en) 1994-02-11 1994-04-06 Zeneca Ltd Pyrrolidine derivatives
EP0804465B1 (en) 1994-06-02 2003-08-06 Aventis Pharmaceuticals Inc. Novel elastase inhibitors
NZ284766A (en) 1994-06-02 1998-06-26 Merrell Pharma Inc Perfluoro amino ketones; medicaments as elastase inhibitors
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
GB9502152D0 (en) 1995-02-03 1995-03-29 Zeneca Ltd Proline derivatives
CA2250209A1 (en) 1996-03-28 1997-10-09 Glaxo Group Limited Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
EP0850252B1 (en) 1996-04-12 2005-06-08 American National Red Cross Mutant plasminogen activator-inhibitor type 1 (pai-1) and uses thereof
PE107899A1 (es) 1997-09-09 1999-11-17 Glaxo Group Ltd Derivados de pirrolopirrolona como inhibidores de elastasa leucocitaria
GB9719187D0 (en) 1997-09-09 1997-11-12 Glaxo Group Ltd Compounds
WO2000032216A1 (en) 1998-06-03 2000-06-08 Cortech Inc. Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors
KR20010078724A (ko) 1998-06-03 2001-08-21 존 더블류. 갈루치 2세 세린 프로테아제 저해제로서의 인돌 및테트라히드로이소퀴놀린을 함유하는 α-케토 옥사디아졸
US20030069187A1 (en) 2001-10-05 2003-04-10 Rao Srinivasa K. Elastase inhibitors
US20030119073A1 (en) 2001-12-21 2003-06-26 Stephen Quirk Sensors and methods of detection for proteinase enzymes
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
TW200500341A (en) 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302324D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302323D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
ES2428503T3 (es) 2004-02-26 2013-11-08 Bayer Intellectual Property Gmbh 1,4-Diaril-dihidropirimidin-2-onas y su uso como inhibidores de elastasa de neutrófilos humanos
JP4825194B2 (ja) 2004-02-26 2011-11-30 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト １，４−ジアリール−ジヒドロピリミジン−２−オン化合物およびヒト好中球エラスターゼ阻害剤としてのそれらの使用
WO2006070012A1 (en) 2004-12-30 2006-07-06 Ingenium Pharmaceuticals Ag Agents useful in treating inflammatory bowel disease
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
GB0512940D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Compounds and their use
GB0605469D0 (en) 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
DE602007009095D1 (de) 2006-05-04 2010-10-21 Pulmagen Therapeutics Inflamma Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase
WO2009013444A1 (en) 2007-07-25 2009-01-29 Argenta Discovery Limited Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
JP5270538B2 (ja) 2006-05-23 2013-08-21 アイアールエム・リミテッド・ライアビリティ・カンパニー チャネル活性化プロテアーゼ阻害剤としての化合物および組成物
CA2651762A1 (en) 2006-05-23 2007-11-29 Irm Llc Compounds and compositions as channel activating protease inhibitors
ES2293832B1 (es) 2006-07-17 2009-05-04 Cargoflet S.A. Sistema de transporte masivo de gas natural a alta presion por via maritima.
EP2064184A1 (en) 2006-09-04 2009-06-03 AstraZeneca AB Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
PL2066662T3 (pl) 2006-09-21 2013-05-31 Kyorin Seiyaku Kk Inhibitory hydrolaz serynowych
RS51644B (sr) 2007-01-10 2011-10-31 Irm Llc. Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
AU2008214217B2 (en) 2007-02-09 2011-10-13 Irm Llc Compounds and compositions as channel activating protease inhibitors
WO2008104752A1 (en) 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
WO2009037413A1 (en) 2007-09-19 2009-03-26 Argenta Discovery Limited Dimers of 5- [ (4-cyanophenyl) sulfinyl] -6-methyl-2-oxo-1- [3- (trifluoromethyl)phenyl] -1,2-dihydropyridine-3-carboxamide as inhibitors of human neutrophil elastase for treating respiratory diseases
WO2009058076A1 (en) 2007-11-02 2009-05-07 Astrazeneca Ab 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
EP2217591A4 (en) 2007-11-06 2011-10-26 Astrazeneca Ab CERTAIN 2-PYRAZINONE DERIVATIVES AND THEIR USE AS NEUTROPHILES ELASTASE INHIBITORS
WO2009060206A1 (en) 2007-11-07 2009-05-14 Argenta Discovery Limited 3,4,6,7-tetrahydro-1h-pyrrolo[3,4-d]pyrimidine-2,5-diones and their therapeutic use
WO2009060158A1 (en) 2007-11-07 2009-05-14 Argenta Discovery Limited 4- (4-cyanophenyl) -1- (3-trifluoromethylphenyl) -3,4, 6, 7-tetrahydro-1h-pyrrolo [3, 4- d] pyrimidine-2, 5-dione derivatives and their use as human neutrophil elastase inhibitors
GB0817429D0 (en) 2008-09-23 2008-10-29 Argenta Discovery Ltd Enzyme inhibitors
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
AU2010302420B2 (en) 2009-10-02 2013-07-04 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
US20110212181A1 (en) 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
GB201004178D0 (en) 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
GB201004179D0 (en) 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
CA2848557A1 (en) 2011-09-14 2013-03-21 Chiesi Farmaceutici S.P.A. Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors
WO2013084199A1 (en) 2011-12-07 2013-06-13 Universidade De Lisboa Boron heterocycles as new inhibitors of human neutrophil elastase
CA2878792A1 (en) 2012-07-12 2014-01-16 Chiesi Farmaceutici S.P.A. Inhibition of enzymes
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140221335A1 (en) 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9115093B2 (en) 2013-03-04 2015-08-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
CN105873933A (zh) 2013-12-16 2016-08-17 奇斯药制品公司 作为人中性白细胞弹性蛋白酶抑制剂的四氢三唑并嘧啶衍生物
JP6499182B2 (ja) 2013-12-27 2019-04-10 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ 選択的エラスターゼ阻害剤としてのβ−ヘアピンペプチド模倣体
DK3087094T3 (da) 2013-12-27 2022-08-29 Polyphor Ag Betahårnål peptidomimetika som selektive elastase inhibitorer
US9221807B2 (en) 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
WO2015200349A2 (en) * 2014-06-24 2015-12-30 The California Institute For Biomedical Research Elastase inhibitors
US9458113B2 (en) 2014-07-31 2016-10-04 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9440930B2 (en) 2014-07-31 2016-09-13 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9290457B2 (en) 2014-07-31 2016-03-22 Boehringer Ingelheim International Gmbh Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9475779B2 (en) 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2016020070A1 (en) 2014-08-05 2016-02-11 Gerard Voerman Mutants of leech derived neutrophil elastase inhibitors and uses thereof
WO2016050835A2 (en) 2014-10-02 2016-04-07 Ruprecht-Karls-Universität Heidelberg Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component
US9890169B2 (en) 2015-12-14 2018-02-13 Chiesi Farmaceutici S.P.A. Triazolinone compounds as HNE inhibitors
WO2017207430A1 (en) 2016-05-31 2017-12-07 Chiesi Farmaceutici S.P.A. Imidazolone compounds as human neutrophil elastase inhibitors
WO2018154568A1 (en) * 2017-02-21 2018-08-30 Kamada Ltd. Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases
JP7672641B2 (ja) * 2019-09-17 2025-05-08 メレオ バイオファーマ ４ リミテッド 移植片拒絶反応、閉塞性細気管支炎症候群、及び移植片対宿主病の治療に使用するためのアルベレスタット
WO2021178448A1 (en) * 2020-03-02 2021-09-10 Motor Life Sciences, Llc Compositions and methods for diagnosing, preventing, and treating amyotrophic lateral sclerosis in patients with hypofunctional anti-trypsin activity

Also Published As

Publication number Publication date
EP4252850A3 (en) 2023-11-15
FI4106757T3 (fi) 2023-10-23
WO2021209740A1 (en) 2021-10-21
IL297211B1 (en) 2025-08-01
SI4106757T1 (sl) 2023-11-30
EP4106757B1 (en) 2023-08-23
EP4106757A1 (en) 2022-12-28
HRP20231065T1 (hr) 2023-12-22
US20230190723A1 (en) 2023-06-22
MX2022012942A (es) 2023-01-11
US20230218596A1 (en) 2023-07-13
PT4106757T (pt) 2023-11-17
EP4252850A2 (en) 2023-10-04
IL297211A (en) 2022-12-01
HUE064089T2 (hu) 2024-02-28
JP2023522010A (ja) 2023-05-26
ES2962498T3 (es) 2024-03-19
PL4106757T3 (pl) 2024-01-22
WO2021209739A1 (en) 2021-10-21
DK4106757T3 (da) 2023-10-23
AU2021256835A1 (en) 2022-10-13
IL297211B2 (en) 2025-12-01

Similar Documents

Publication Publication Date Title
LT4106757T (lt) Neutrofilų elastazės inhibitoriaus alvelestato panaudojimas kvėpavimo sistemos ligų, nulemtų alfa-1 antitripsino nepakankamumo, gydymui
PH12021550187A1 (en) Pyrrolopyrimidine itk inhibitors
UA118149C2 (uk) Інгібітор jak
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
NO20084502L (no) Tetrahydropyrrolopyrimidinedioner og deres anvendelse som humane neutrofil elastase inhibitorer
NO20076206L (no) Kombinasjon av PDE4 inhibitor romflumilast og et tetrahydrobioterin-derivativ
MX384624B (es) Derivados de pirazol como inhibidores de calicreina plasmatica.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
EA201490949A1 (ru) Ингибиторы киназ
ATE459615T1 (de) 2-pyridonderivate zur behandlung von krankheiten oder leiden, bei denen eine inhibierung der aktivität der neutrophilen elastase von nutzen ist
CY1117123T1 (el) Παραγωγα οιστρα-1,3,5(10),16-τετραενο-3- καρβοξαμιδιου, μεθοδοι για την παραγωγη αυτων, φαρμακευτικα παρασκευασματα που τα περιεχουν καθως και η χρηση αυτων για την παραγωγη φαρμακευτικων μεσων
MX2016001865A (es) Inhibidores biciclicos.
CU20150091A7 (es) Estra-1, 3,5(10), 16tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
IL287704A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
BR112022014861A2 (pt) Métodos de tratamento para deficiência de alfa-1 antittripsina
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
ATE446098T1 (de) Verwendung von polyethylenglycol bei entzündungsbedingten topischen erkrankungen oder erkrankungen und wundheilung
ATE475651T1 (de) Aryl-substituierte heterozyklen und ihre verwendung
ATE402924T1 (de) Pyridiniumsalze und deren verwendung
DE502005002176D1 (de) Substituierte chinolone
IL285042A (en) Methods of producing and using recombinant alpha 1-antitrypsin (aat) and compositions thereof
EP4119165A4 (en) NOVEL 3,5-DIAMINOBENZOIC ACID COMPOUND, AND PIN1 INHIBITOR AND THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES USING SAME
BR112014006196A2 (pt) sais de ácido sulfônico de imidazolas substituídas por heterociclilamidas
ATE420089T1 (de) Substituierte azachinazoline mit antiviraler wirkung